Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.46 |
| ▸ | OPRM1 | P35372 | 9/20 | 0.44 |
| ▸ | OPRD1 | P41143 | 9/20 | 0.44 |
| ▸ | OPRK1 | P41145 | 9/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.43 |
| ▸ | BCHE | P06276 | 1/20 | 0.40 |
| ▸ | NMT2 | O60551 | 1/20 | 0.40 |
| ▸ | NMT1 | P30419 | 1/20 | 0.40 |
| ▸ | CCR5 | P51681 | 1/20 | 0.40 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4681557 | 0.81 | OPRM1 (0.42) | OPRM1OPRD1OPRK1ENPP2 | |
| SCHEMBL6897427 | 0.81 | SLC6A3 (0.53) | — | |
| SCHEMBL18976829 | 0.81 | NPC1 (0.51) | SLC18A3SIGMAR1BCHE | |
| SCHEMBL7419921 | 0.79 | SLC18A3 (0.60) | SLC18A3OPRM1OPRD1OPRK1SIGMAR1 | |
| SCHEMBL2440428 | 0.79 | SLC18A3 (0.60) | SLC18A3OPRM1OPRD1OPRK1SIGMAR1 | |
| SCHEMBL9133642 | 0.79 | SLC18A3 (0.60) | SLC18A3OPRM1OPRD1OPRK1SIGMAR1 | |
| SCHEMBL2197741 | 0.79 | PPM1D (0.53) | SLC18A3SIGMAR1CCR5 | |
| SCHEMBL23642788 | 0.79 | SLC18A3 (0.40) | SLC18A3OPRM1OPRD1OPRK1SIGMAR1 | |
| SCHEMBL17565146 | 0.79 | SLC6A3 (0.54) | SLC18A3 | |
| SCHEMBL612124 | 0.77 | SIGMAR1 (0.46) | OPRM1OPRD1OPRK1SIGMAR1BCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110172230-A1 | UREA COMPOUND OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2011-07-14 | — | — | US | disclosed |
| EP-2065369-A1 | UREA COMPOUND OR SALT THEREOF | Astellas Pharma Inc. (JP) | 2009-06-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172230-A1 | UREA COMPOUND OR SALT THEREOF | FAAH, FAAH2, UTS2R | SLC18A3 1087/4885OPRM1 495/4885OPRD1 1118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.